Soleno Therapeutics GAAP EPS of $0.80 beats by $0.09, revenue of $91.73M beats by $3.18M
Source: SeekingAlpha
2026-02-25 17:13:40 ET
More on Soleno Therapeutics
- Soleno Therapeutics: Why I'm Staying On The Sidelines
- Seeking Alpha’s Quant Rating on Soleno Therapeutics
- Historical earnings data for Soleno Therapeutics
- Financial information for Soleno Therapeutics
Read the full article on Seeking Alpha
For further details see:
Soleno Therapeutics GAAP EPS of $0.80 beats by $0.09, revenue of $91.73M beats by $3.18M
Soleno Therapeutics Inc.
NASDAQ: SLNO
SLNO Trading
-7.13% G/L:
$36.77 Last:
876,084 Volume:
$38.67 Open:
SLNO Latest News
March 12, 2026 09:00:00 am
SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt
March 10, 2026 08:00:00 am
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
March 09, 2026 12:48:00 pm
Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights
February 26, 2026 08:00:00 am
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
SLNO Stock Data
$2,184,386,717
45,438,681
1.25%
73
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
